ReviewCurrent allergy and asthma reports2017
Predictive Biomarkers for Asthma Therapy.
Review in Current allergy and asthma reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2020Trial
- Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.BMC pulmonary medicine · 2019Trial
- Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST).The journal of allergy and clinical immunology. In practiceTrial
- Review
- Overall perspective of electrospun semiconductor metal oxides as high-performance gas sensor materials for NORSC advances · 2024Review
- Review
- Switching Biological Therapies in Severe Asthma.International journal of molecular sciences · 2023Review
- Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice.International journal of molecular sciences · 2023Review
- Tentative study on radial endobronchial ultrasonography evaluating airway wall thickness before and after bronchial thermoplasty.Respiratory medicine case reports · 2022Article
- Understanding the Cellular Sources of the Fractional Exhaled Nitric Oxide (FeNO) and Its Role as a Biomarker of Type 2 Inflammation in Asthma.BioMed research international · 2022Review
- Which Therapy for Non-Type(T)2/T2-Low Asthma.Journal of personalized medicine · 2021Review
- The Role of Dupilumab in Severe Asthma.Biomedicines · 2021Review
- Comparing Patient Characteristics, Clinical Outcomes, and Biomarkers of Severe Asthma Patients in Taiwan.Biomedicines · 2021Article
- Nasal DNA methylation differentiates severe from non-severe asthma in African-American children.Allergy · 2021Article
- 2021 Brazilian Thoracic Association recommendations for the management of severe asthma.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021Review
- Exploration of the sputum methylome and omics deconvolution by quadratic programming in molecular profiling of asthma and COPD: the road to sputum omics 2.0.Respiratory research · 2020Article
- Factors that affect blood eosinophil counts in a non-asthmatic population: Post hoc analysis of data from Brazil.The World Allergy Organization journal · 2020Article
- Biomarkers of Bronchial Asthma.Physiological research · 2020Review
- Measuring inflammation in paediatric severe asthma: biomarkers in clinical practice.Breathe (Sheffield, England) · 2020Review
- Molecular Analysis of IL-5 Receptor Subunit Alpha as a Possible Pharmacogenetic Biomarker in Asthma.Frontiers in medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAsthma is a heterogeneous disease characterized by multiple phenotypes. Treatment of patients with severe disease can be challenging. Predictive biomarkers are measurable characteristics that reflect the underlying pathophysiology of asthma and can identify patients that are likely to respond to a given therapy. This review discusses current knowledge regarding predictive biomarkers in asthma. RECENT
findingsRecent trials evaluating biologic therapies targeting IgE, IL-5, IL-13, and IL-4 have utilized predictive biomarkers to identify patients who might benefit from treatment. Other work has suggested that using composite biomarkers may offer enhanced predictive capabilities in tailoring asthma therapy. Multiple biomarkers including sputum eosinophil count, blood eosinophil count, fractional concentration of nitric oxide in exhaled breath (FeNO), and serum periostin have been used to identify which patients will respond to targeted asthma medications. Further work is needed to integrate predictive biomarkers into clinical practice.
Indexed as
Identifiers
28929293What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.